NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine
February 11, 2022 08:01 ET
|
NRx Pharmaceuticals, Inc.
Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaperBriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines,...
NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments
January 18, 2022 06:48 ET
|
NRx Pharmaceuticals, Inc.
ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded...
NRx Responds to Relief’s Allegations of January 14, 2022
January 14, 2022 14:34 ET
|
NRx Pharmaceuticals, Inc.
Neither NRx nor Jonathan Javitt accused current Relief management or board of a criminal past. The lawsuit identifies FINRA actions against Dr. Sevelraju, prior securities investigation, and civil...
NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant
January 11, 2022 07:54 ET
|
NRx Pharmaceuticals, Inc.
Trial targeted to begin in the first quarter of 2022NRx is coordinating study with the US Health and Human Services Biomedical Advanced Research and Development Authority and several European...
NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine
January 07, 2022 17:50 ET
|
NRx Pharmaceuticals, Inc.
New details of clinical trial for BriLife™ to be discussed during company update presentation at the H.C. Wainwright BioConnect Virtual ConferenceCompany presentation time changed to 9 AM EST on...
NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual Conference
January 07, 2022 06:48 ET
|
NRx Pharmaceuticals, Inc.
Conference Begins on January 10, 2022 RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of...
NRx Pharmaceuticals Added to the Nasdaq® Biotech Index
December 15, 2021 06:48 ET
|
NRx Pharmaceuticals, Inc.
The Nasdaq Biotechnology Index (NBI) is a market index comprised of Nasdaq® listed Biotechnology and Pharmaceutical companies New classification is effective prior to the market open on Monday,...
NRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
December 14, 2021 06:48 ET
|
NRx Pharmaceuticals, Inc.
After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to...
NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine Trials
December 09, 2021 09:21 ET
|
NRx Pharmaceuticals, Inc.
NRx and Hungary Agree on Regulatory Path for Emergency Use of ZYESAMIHungary to Serve as First European Nation for the Registrational Phase 2b/3 BriLife COVID Vaccine Trial BUDAPEST, Hungary, Dec. ...
NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions
December 06, 2021 09:07 ET
|
NRx Pharmaceuticals, Inc.
Independent Data Safety Monitoring Board has completed review of BriLife phase 2 trial at low, medium, and high doses, with a formal report expected imminentlyNRx has obtained advice from European...